Products
Gimistotug Biosimilar Monoclonal Antibody (OX40) for Research
Cat No.: GMP-Bios-INN-1216
Anti-TNFRSF4/CD134/OX40 therapeutic antibody (Pre-made Gimistotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gimistotug (development code BGB-A445) is a monoclonal antibody targeting OX40 (TNFRSF4). It is developed by BeiGene for Non-small cell lung cancer, Malignant melanoma, Renal cell carcinoma et al. in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1216-1mg | 1mg | 3090 |
| GMP-Bios-INN-1216-10mg | 10mg | |
| GMP-Bios-INN-1216-100mg | 100mg | |
| GMP-Bios-INN-1216-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gimistotug biosimilar, Whole mAb, Anti-TNFRSF4/CD134/OX40 Antibody: Anti-CD134/OX40/TNFRSF4/Tumor necrosis factor receptor superfamily member 4 therapeutic antibody |
| INN Name | Gimistotug |
| Target | TNFRSF4/CD134/OX40 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | BeiGene |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Urogenital cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
